Spectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients.
Anti-epidermal growth factor receptor (EGFR) therapy has been tried in triple negative breast cancer (TNBC) patients without evaluation of molecular and clinical predictors in several randomized clinical studies. Only fewer than 20% of metastatic TNBCs showed response to anti-EGFR therapy. In order...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2013-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC3813621?pdf=render |
| _version_ | 1819135154995593216 |
|---|---|
| author | Yoonjung Kim Juwon Kim Hy-De Lee Joon Jeong Woochang Lee Kyung-A Lee |
| author_facet | Yoonjung Kim Juwon Kim Hy-De Lee Joon Jeong Woochang Lee Kyung-A Lee |
| author_sort | Yoonjung Kim |
| collection | DOAJ |
| description | Anti-epidermal growth factor receptor (EGFR) therapy has been tried in triple negative breast cancer (TNBC) patients without evaluation of molecular and clinical predictors in several randomized clinical studies. Only fewer than 20% of metastatic TNBCs showed response to anti-EGFR therapy. In order to increase the overall response rate, first step would be to classify TNBC into good or poor responders according to oncogenic mutation profiles. This study provides the molecular characteristics of TNBCs including EGFR gene copy number changes and mutation status of EGFR and KRAS gene in Korean TNBC patients. Mutation analysis for EGFR, KRAS, BRAF and TP53 from a total of 105 TNBC tissue samples was performed by direct sequencing, peptide nucleic acid-mediated PCR clamping method and real-time PCR. Copy number changes of EGFR gene were evaluated using multiplex ligation-dependent probe amplification. Out of all 105 TNBCs, 15.2% (16/105) showed EGFR copy number changes. Among them, increased or decreased EGFR copy number was detected in 13 (5 single copy gain, 2 amplification and 4 high-copy number amplification) and 3 cases (3 hemizygous deletion), respectively. The mutation frequencies of KRAS, EGFR and TP53 gene were 1.9% (G12V and G12D), 1.0% (exon 19 del) and 31.4%, respectively. There was no BRAF V600E mutation found. Future studies are needed to evaluate the clinical outcomes of TNBC patients who undergo anti-EGFR therapy according to the genetic status of EGFR. |
| first_indexed | 2024-12-22T10:14:35Z |
| format | Article |
| id | doaj.art-2cd0f7e5b25c4b82a951146b1c0397d1 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-12-22T10:14:35Z |
| publishDate | 2013-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-2cd0f7e5b25c4b82a951146b1c0397d12022-12-21T18:29:45ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-01810e7901410.1371/journal.pone.0079014Spectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients.Yoonjung KimJuwon KimHy-De LeeJoon JeongWoochang LeeKyung-A LeeAnti-epidermal growth factor receptor (EGFR) therapy has been tried in triple negative breast cancer (TNBC) patients without evaluation of molecular and clinical predictors in several randomized clinical studies. Only fewer than 20% of metastatic TNBCs showed response to anti-EGFR therapy. In order to increase the overall response rate, first step would be to classify TNBC into good or poor responders according to oncogenic mutation profiles. This study provides the molecular characteristics of TNBCs including EGFR gene copy number changes and mutation status of EGFR and KRAS gene in Korean TNBC patients. Mutation analysis for EGFR, KRAS, BRAF and TP53 from a total of 105 TNBC tissue samples was performed by direct sequencing, peptide nucleic acid-mediated PCR clamping method and real-time PCR. Copy number changes of EGFR gene were evaluated using multiplex ligation-dependent probe amplification. Out of all 105 TNBCs, 15.2% (16/105) showed EGFR copy number changes. Among them, increased or decreased EGFR copy number was detected in 13 (5 single copy gain, 2 amplification and 4 high-copy number amplification) and 3 cases (3 hemizygous deletion), respectively. The mutation frequencies of KRAS, EGFR and TP53 gene were 1.9% (G12V and G12D), 1.0% (exon 19 del) and 31.4%, respectively. There was no BRAF V600E mutation found. Future studies are needed to evaluate the clinical outcomes of TNBC patients who undergo anti-EGFR therapy according to the genetic status of EGFR.http://europepmc.org/articles/PMC3813621?pdf=render |
| spellingShingle | Yoonjung Kim Juwon Kim Hy-De Lee Joon Jeong Woochang Lee Kyung-A Lee Spectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients. PLoS ONE |
| title | Spectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients. |
| title_full | Spectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients. |
| title_fullStr | Spectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients. |
| title_full_unstemmed | Spectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients. |
| title_short | Spectrum of EGFR gene copy number changes and KRAS gene mutation status in Korean triple negative breast cancer patients. |
| title_sort | spectrum of egfr gene copy number changes and kras gene mutation status in korean triple negative breast cancer patients |
| url | http://europepmc.org/articles/PMC3813621?pdf=render |
| work_keys_str_mv | AT yoonjungkim spectrumofegfrgenecopynumberchangesandkrasgenemutationstatusinkoreantriplenegativebreastcancerpatients AT juwonkim spectrumofegfrgenecopynumberchangesandkrasgenemutationstatusinkoreantriplenegativebreastcancerpatients AT hydelee spectrumofegfrgenecopynumberchangesandkrasgenemutationstatusinkoreantriplenegativebreastcancerpatients AT joonjeong spectrumofegfrgenecopynumberchangesandkrasgenemutationstatusinkoreantriplenegativebreastcancerpatients AT woochanglee spectrumofegfrgenecopynumberchangesandkrasgenemutationstatusinkoreantriplenegativebreastcancerpatients AT kyungalee spectrumofegfrgenecopynumberchangesandkrasgenemutationstatusinkoreantriplenegativebreastcancerpatients |